Companies
Q-linea
its ASTar system runs rapid phenotypic antibiotic susceptibility testing directly from positive blood culture, and the company recently announced FDA clearance of an expanded ASTar blood-testing menu, extending the platform's antibiotic and pathogen coverage.
- Country
- Sweden
Growth
ASTar system
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | SEK 312 million rights issue completed in November 2025 | qlinea.com |
| Capacity | Internalized consumables production and antibiotic filling/drying process increased production capacity | qlinea.com |
| Certification | CE-IVDR certification for ASTar instrument and consumables | qlinea.com · storage.mfn.se |
| Regulatory approval | FDA 510(k) clearance for ASTar system (April 2024) and expanded Gram-negative Blood Culture menu (April 2026) | qlinea.com · storage.mfn.se |
| Production site | Consumables production premises on Palmbladsgatan, Uppsala, Sweden | qlinea.com |
| Headcount | 70 employees as of June 30, 2026 | stockanalysis.com |
| Revenue | 15.29M SEK for the full year 2025 | stockanalysis.com |
Independent sources: stockanalysis.com · storage.mfn.se
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Rapid antibiotic-resistance tests | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.